ConductScience.org, home

Paper34716976

How translational modeling in oncology needs to get the mechanism just right.

Yates JWT and 1 other. Clin Transl Sci, 2022. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. How translational modeling in oncology needs to get the mechanism just right. Papers, record 34716976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34716976

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
How translational modeling in oncology needs to get the mechanism just right.
PubMed
Journal
Clin Transl Sci
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.64
iCite
Revised in PubMed
2022-05-02
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yates JWTJames W T
2Fairman DADavid A

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
Animals
Humans
Medical Oncology

References97

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131338741Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to.Bull Math Biol2019https://conductscience.org/library/papers/31338741PubMed
229761883Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance.CPT Pharmacometrics Syst Pharmacol2018https://conductscience.org/library/papers/29761883PubMed
31004590Predicting the course of Gompertzian growth.Nature1976https://conductscience.org/library/papers/1004590PubMed
42250141A nonlinear structured population model of tumor growth with quiescence.J Math Biol1990https://conductscience.org/library/papers/2250141PubMed
520424896Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.J Pharmacokinet Pharmacodyn2010https://conductscience.org/library/papers/20424896PubMed
68993512Schedule-dependent efficacy of camptothecins in models of human cancer.Ann N Y Acad Sci1996https://conductscience.org/library/papers/8993512PubMed
734716976How translational modeling in oncology needs to get the mechanism just right.Clin Transl Sci2022https://conductscience.org/library/papers/34716976PubMed
828722322Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).CPT Pharmacometrics Syst Pharmacol2017https://conductscience.org/library/papers/28722322PubMed
95965750Growth rate and radiosensitivity of human tumours. I. Growth rate of human tumours.Eur J Cancer (1965)1966https://conductscience.org/library/papers/5965750PubMed
1021819622Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.BMC Cancer2011https://conductscience.org/library/papers/21819622PubMed
1130739743Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.Lancet2019https://conductscience.org/library/papers/30739743PubMed
1229470495Reproducibility of preclinical animal research improves with heterogeneity of study samples.PLoS Biol2018https://conductscience.org/library/papers/29470495PubMed
1325470047Cancer: Resistance through repopulation.Nature2015https://conductscience.org/library/papers/25470047PubMed
1414219541DYNAMICS OF TUMOR GROWTH.Br J Cancer1964https://conductscience.org/library/papers/14219541PubMed
1531375756A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.Sci Rep2019https://conductscience.org/library/papers/31375756PubMed
1626310312Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738.Sci Rep2015https://conductscience.org/library/papers/26310312PubMed
176387060The importance of dose intensity in chemotherapy of metastatic breast cancer.J Clin Oncol1984https://conductscience.org/library/papers/6387060PubMed
183191483A Gompertzian model of human breast cancer growth.Cancer Res1988https://conductscience.org/library/papers/3191483PubMed
1924850445Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.CPT Pharmacometrics Syst Pharmacol2014https://conductscience.org/library/papers/24850445PubMed
207634381Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7634381PubMed

See all 97 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
38751464Features and applications of Ehrlich tumor model in cancer studies: a literature review.Transl Breast Cancer Res2023https://conductscience.org/library/papers/38751464PubMed
37930506Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model.J Pharmacokinet Pharmacodyn2024https://conductscience.org/library/papers/37930506PubMed
37771203Skipping a pillar does not make for strong foundations: Pharmacokinetic-pharmacodynamic reasoning behind the shape of dose-response relationships in oncology.CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37771203PubMed
35189161Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs.Pharmacol Ther2022https://conductscience.org/library/papers/35189161PubMed
34716976How translational modeling in oncology needs to get the mechanism just right.Clin Transl Sci2022https://conductscience.org/library/papers/34716976PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34716976

GET https://conductscience.org/api/papers/v1/34716976/references?page=2